Propanc Biopharma (PPCB) Registration filing summary

Company overview and business model

• Focuses on developing novel cancer treatments targeting pancreatic, ovarian, and colorectal cancers using a proprietary pro-enzyme therapy (PRP) designed to prevent recurrence and metastasis by targeting cancer stem cells.

• Lead product PRP is in preclinical development, with plans for a Phase Ib clinical trial in advanced solid tumors, subject to additional financing.

• Holds 85 granted patents and 5 pending applications globally for proenzyme-based cancer therapies.

• Operates primarily from Australia, with research collaborations in Europe and a subsidiary in the UK for regulatory purposes.

Financial performance and metrics

• No revenue generated for the years ended June 30, 2025 and 2024; operations funded through equity and convertible debt.

• Net loss of $58.9 million for the year ended June 30, 2025, compared to $1.8 million in 2024, driven by a significant increase in stock-based compensation and consulting expenses.

• Accumulated deficit of $125.6 million as of June 30, 2025; cash balance of $12,088 at June 30, 2025 and $561,237 at December 31, 2025.

• Negative cash flows from operations: $405,168 for the year ended June 30, 2025 and $2,938,207 for the six months ended December 31, 2025.

• Substantial reliance on external financing, including $3.3 million net proceeds from an August 2025 public offering and $1 million from a Series C Preferred Stock private placement.

Use of proceeds and capital allocation

• Proceeds from recent financings allocated to working capital, capital expenditures, product development, and general corporate purposes, with no specific allocations disclosed.

• No proceeds from the resale of shares by the selling stockholder; company only receives funds if Series C warrants are exercised.